Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Enrolling by invitation × Gastrointestinal × Clear all

Phase

Phase NA 51 Phase 2 11 Phase 1/2 5 Phase EARLY_PHASE1 3 Phase 3 2 Phase 4 1 Phase 2/3 1 Phase 1 1

Status

Unknown 93 Completed 77 Recruiting 51 Terminated 24 Not yet recruiting 24 Active not recruiting 17 Withdrawn 14 Suspended 4 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1

Conditions

Neoplasm Metastasis 1 Cholangiocarcinoma 1

Interventions

futibatinib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06506955 2026-03-11

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

Taiho Oncology, Inc.

Phase 2/3 Enrolling by invitation

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡